Financial Performance - The total revenue for 2022 was RMB 7,502,987,102.09, representing a 14.37% increase from RMB 6,560,077,586.40 in 2021[4]. - The net profit attributable to shareholders of the listed company was RMB 411,193,683.53, an increase of 17.97% compared to RMB 348,548,495.99 in the previous year[4]. - The operating cash flow net amount reached RMB 758,240,601.50, showing a significant increase of 192.62% from RMB 259,116,960.17 in 2021[4]. - The basic earnings per share increased to RMB 0.62, a rise of 10.71% from RMB 0.56 in the previous year[4]. - The diluted earnings per share also increased to RMB 0.61, reflecting an 8.93% growth compared to RMB 0.56 in 2021[4]. - The total comprehensive income for the year was RMB 413,373,076.38, up from RMB 313,908,790.25 in 2021, showing a growth of 31.69%[49]. - The operating profit for the year ended December 31, 2022, was RMB 476,706,533.91, compared to RMB 425,590,536.88 in 2021, indicating an increase of about 12.0%[54]. Assets and Liabilities - Total assets as of December 31, 2022, were RMB 8,265,131,332.13, up 12.73% from RMB 7,332,033,657.98 at the end of 2021[5]. - The total liabilities increased by 6.37% to RMB 3,915,226,169.32 from RMB 3,680,888,823.85 in the previous year[5]. - The net assets attributable to shareholders of the listed company rose by 18.99% to RMB 4,126,460,390.95 from RMB 3,467,941,567.45 in 2021[5]. - Current liabilities totaled RMB 3,158,485,539.10 as of December 31, 2022, compared to RMB 2,501,880,371.20 in 2021, indicating a significant increase of 26.29%[47]. - Long-term borrowings increased to RMB 545,655,801.48 in 2022 from RMB 346,196,870.64 in 2021, representing a growth of 57.67%[47]. Shareholder Information - As of December 31, 2022, the total number of shareholders was 107,300, including 38 H-share shareholders and 107,262 A-share shareholders[8]. - The proposed final dividend for the year 2022 is RMB 0.20 per share (before tax), subject to shareholder approval[12]. - The largest shareholder, China Hualu Holdings Group Co., Ltd., holds 30.59% of the shares, totaling 204,864,092 shares[10]. - The company emphasizes the importance of shareholder approval for the proposed dividend distribution[12]. - The proposed dividend for 2022 represents a 33.33% increase compared to the previous year's dividend[81]. Cash Flow and Investments - Cash and cash equivalents increased by 55.61% to RMB 1,158,741,565.90 compared to RMB 744,662,302.34 last year, primarily due to net proceeds from a non-public offering of A-shares amounting to RMB 244 million and an increase in customer prepayments[18][20]. - Net cash flow from operating activities reached RMB 758,240,601.50, a substantial increase of 192.62% compared to RMB 259,116,960.17 last year[23][24]. - The company achieved a fixed asset investment of RMB 720 million for the year, representing a year-on-year increase of 21%[30]. Research and Development - Research and development expenses increased by 1.26% to RMB 345,658,511.77 from RMB 341,367,394.20, reflecting ongoing investment in innovation[21]. - The company obtained 7 new product approvals for formulations and 4 for raw materials in 2022, including significant breakthroughs in drug innovation[29]. - The company plans to accelerate the development of new products, focusing on fish oil, hormones, and other specialty raw materials[33]. Market Performance - The sales revenue of the top 10 strategic formulations increased by 30% year-on-year, with the sales of fish oil soft capsules exceeding RMB 10 million[29]. - The international formulations and contract manufacturing sales saw an impressive year-on-year growth of 88%[29]. - The revenue from external transactions for the chemical raw materials segment was RMB 3,171,564,382.95 for the year ended December 31, 2022, compared to RMB 2,740,737,136.77 in 2021, marking an increase of approximately 15.7%[53]. Operational Efficiency - The company achieved a receivables turnover rate of 1,056.89% and an inventory turnover rate of 488.11% as of December 31, 2022[26]. - The company aims to enhance production efficiency and cost control through lean production and procurement management strategies[37]. - The company completed 30 technical quality projects and 21 energy transformation projects, saving RMB 20.9 million in raw material and energy consumption[30]. Compliance and Governance - The audit for the financial statements was conducted by Shinewing Certified Public Accountants, ensuring compliance with Chinese accounting standards[39]. - The company has established an audit committee to oversee financial reporting and internal controls, meeting four times during the year[44].
山东新华制药股份(00719) - 2022 - 年度业绩